Presentation is loading. Please wait.

Presentation is loading. Please wait.

CORRELATION BETWEEN HIV-1 MOLECULAR CHARACTERISTICS AND RESPONSE TO HAART IN PEDIATRIC POPULATION FROM SAO PAULO, BRAZIL Cristina Mendes de Oliveira, Rosangela.

Published byAmber Paul Modified over 7 years ago

Similar presentations

Presentation on theme: "CORRELATION BETWEEN HIV-1 MOLECULAR CHARACTERISTICS AND RESPONSE TO HAART IN PEDIATRIC POPULATION FROM SAO PAULO, BRAZIL Cristina Mendes de Oliveira, Rosangela."— Presentation transcript:

1 CORRELATION BETWEEN HIV-1 MOLECULAR CHARACTERISTICS AND RESPONSE TO HAART IN PEDIATRIC POPULATION FROM SAO PAULO, BRAZIL Cristina Mendes de Oliveira, Rosangela Rodrigues, Carla M P Vazquez, Maria do Socorro Carneiro Ferrão, Alexandre Campeas, Márcia Crozatti, Silvia Marques, Luis Fernando de Macedo Brígido. Laboratório de Retrovírus, Instituto Adolfo Lutz, São Paulo, Brasil Instituto de Infectologia Emílio Ribas, são Paulo, Brasil

2 Decision on when to start ARV therapy is a matter of controversy even for adults Children pose additional challenges even in virological failure due to specific issues, including: –Potential interference with normal growth and development –Toxicity; Pharmaco-dynamics –Limited ARV options; posology limitations –Adherence

3 What is the contribution of molecular information to the management of children living with HIV/AIDS ARV drug resistance test were the fist molecular characterization brought into clinical practice routine, subsidizing salvage ARV therapy. Additional molecular characteristics of HIV-1 that provide surrogate markers do determine when and how to treat HIV infected children can be useful in subsidizing decision on starting as well as changing ARV therapy.

4 Methodology Inclusion criteriaInclusion criteria Informed consent from parents or gardian and additional informal consent for older children at inclusion visit Informed consent from parents or gardian and additional informal consent for older children at inclusion visit Naïve : samples collected before initiation of ARV (2001-2006) Treated : children or adolescent using EFV or LPV based HAART ( collected from 6 / 2005 to 11 / 2006 ) Viral load bDNA (Bayer); TCD4 ( BD), performed at certified National Network Laboratory HIV sequencing performed at Retrovirus Laboratory, Adolfo Lutz Institute

5 Samples collected at baseline EDTA blood collected at service and processed within 6 hs Cell lysade and plasma maintained at -70 °C Extraction plasma RNA and/or Cell DNA (Qiagem/GFX) RNA retrotranscrition (Superscript II, Invitrogen, USA) Nested PCR Sequencing (ABI 3100) with Big Dye chemistry (ABI,USA) Edition : Sequencher (Gene codes corp.,USA) Phylogeny : REGA, NCBI, SIMPLOT, PAUP Drug Resistance Mutations (DRM), Stanford HIV Database

6

7 Baseline Characteristics Naïve Treated n=16 n=79 Age (mean years ) 3.6 9.4 Gender (% males) 44% 54% Mean number of ARV regimens 0 5.7 TCD4 ( cels/mm 3 ) 1108 650 Plasma Viremia (log) 4.91 4.08 % undetectable 0% 24%

8 Clinical outcome of ARV treated cases 78 cases with follow up information 79.5% Asymptomatic 7% Bacterial Pneumonia 4% TB Other complications One death (adenocarcinoma) One loss to follow up (change town) - Citopenias in 6% - Pancreatitis - CMV

9 Outcome categories defined based on : (i)Viral load at last observation (end 2007- first semester of 2008) (ii)Clinical observation (patients’ pediatrician) at last documented visit and TCD4 cell counts (cells / mm3) at last observation GOOD RESPONDERS TCD4 counts over 350 and clinically asymptomatic POOR RESPONDERS TCD4 counts under 350 or clinical Aids related condition

10 Viral Load and TCD4 outcome TCD4 mean 650 cels/mm3 TCD4 mean 691cels/mm3 61% with TCD4 over 500 27% 200 - 500 12% below 200 24% aviremic - among viremic Log 10 4.54 35% aviremic - among viremic Log 10 3.91 At baseline At last visit

11 Treatment at last evaluation NNRTIs + EFV and/or LPV based HAART ARVAvir GR LPV 65%41%62% EFV 21%23%67% EFV+LPV 12%40%80%

12 Age (mean) % males number regimens (mean) Time on ARV (weeks) Time of follow up (weeks) % avir at baseline * Baseline Viremia among viremic Avir (<50c/ML) 8.7483.1395106524.62 Vir 2-4 Log 10 9.5423.4445105174.13 Vir> 4 Log 10 9.9574.250610454.71 Baseline characteristics by Virological outcome * P< 0.002

13 Presence of DRMs by virological strata TAM NRTI. DRM NNRTI DRM PI. DRM PI. sec/acc PI Major DRM Vir>4.03.135.041.226.1351.13 vir2-42.753.851.193.252.630.63 Avir2.683.941.252.822.470.35 Vir>4 x Avir P= 0.43 p=0.14 p=0.9 P<0.001 p<0.05 p<0.01 Mean number of DRM at RT and PT DRM Drug Resistance Mutations RT reverse transcriptase gene PT –Protease gene Tam -Tymidine Analogue mutations NRTI -Nucleoside analogue ARV class NNRTI - Non analogue ARV class PI -Protease inhibitor class Sec/acc -Secondary/accessory mutations Major- Principal mutations to PI

14 Proportion of DRM to NRTI class in ARV resistance codons at Reverse transcriptase (RT) by treatment outcome PR poor response; GR good response

15 Proportion of DRM to NNRTI class in ARV resistance codons at Reverse transcriptase (RT) by treatment outcome PR poor response; GR good response

16 Proportion of DRM to Protease Inhibitors (PI) at ARV resistance codon at PROTEASE by treatment outcome

17 Proportion of DRM to Protease Inhibitors (PI) at ARV resistance codon at PROTEASE by treatment outcome PR poor response; GR good response

18 Proportion of DRM to Protease Inhibitors (PI) at ARV resistance codon at PROTEASE by clinical outcome

19 Impact of DRM on treatment outcome V82A/F/T/SL90M GR 9% PR 45% 30% Proportion of selected major DRM at PR p<0.0052 P=0.067

20 Impact of DRM on treatment outcome Among cases currently using LPV based HAART P<0.0082 p=0.2 NNRTINRTI ALL NRTI TAM IP Acc /sec IP major GR1.64.83.12.50.25 PR1.34.33.34.80.90 GR Good responders ; PR Poor responders Mean number of DRM at RT and PT BY outcome

21 Impact of DRM on treatment outcome among cases using EFV based HAART NNRTINRTI ALL NRTI TAM IP Acc /sec IP major GR1.5430.75 0 PR0.34.673 0.3 Mean number of DRM at RT and PT GR Good responders ; PR Poor responders

22 Protease polimorphisms by pol clade

23 V3 loop signatures among naïve and treated cases stratified by poor responders (PR) and good responders (GR)

24 PR GR

25 Recombination patterns at gag (903-1920), pol (2252-3251) and env (7077-7609), positions related to HXB2 ( K03455). HIV-1 B HVI-1 F HIV-1 C BF mosaics

26 HIV-1 clades by virological outcome and clinical outcome

27 Predicted HIV tropism by virological and clinical outcome

28 V3 loop AA alignment of paired cell and plasma

29 Impact V3 mixtures on treatment outcome Proportion of V3 with mixtures Proportion of nu Mixtures N GR49%5.6739 PR44%2.4918 Mean number of Mixtures at V3 by outcome Most sequences ( 51% among GR and 54% among PR) do not show mixtures at V3 P<0.031

30 DIVERSIDADE - DIVERGENCIA intra- hospedeiro Arts et al. 2007

31 Conclusions Albeit treated for over a mean of 449 weeks (8.6 years) over one third of these children had viral load< 50 c/ml at last evaluation Protease inhibitors mutations, both major as well as accessory/ Secondary DRM, correlated to viremia and poor clinical outcome; some polymorphisms common among naïve cases and may have an impact in resistance evolution Presence of mixtures at V3 codons were associated to good clinical outcome

32

Download ppt "CORRELATION BETWEEN HIV-1 MOLECULAR CHARACTERISTICS AND RESPONSE TO HAART IN PEDIATRIC POPULATION FROM SAO PAULO, BRAZIL Cristina Mendes de Oliveira, Rosangela."

Similar presentations

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
Monitoring the emergence of resistance mutations in patients under salvage therapy with Raltegravir in Rio de Janeiro, Brazil: a six month follow-up Caroline.

Monitoring the emergence of resistance mutations in patients under salvage therapy with Raltegravir in Rio de Janeiro, Brazil: a six month follow-up Caroline.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Global HIV Resistance: The Implications of Transmission

Global HIV Resistance: The Implications of Transmission
Nurses SOAR! Training Curricula Series For More Information and Inquiries:

Nurses SOAR! Training Curricula Series For More Information and Inquiries:
Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,

Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,
Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.

Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.
Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI438011 Study  TAF (TFV prodrug) –Study 292-0102 –Study 299-0102  Doravirine.

Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI Study  TAF (TFV prodrug) –Study –Study  Doravirine.
Prevalence of resistance mutations in a cohort of treatment-naïve people with chronic HIV infection in the U.S.: CPCRA 058 R M Novak 1, L Chen 2, R D MacArthur.

Prevalence of resistance mutations in a cohort of treatment-naïve people with chronic HIV infection in the U.S.: CPCRA 058 R M Novak 1, L Chen 2, R D MacArthur.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Naive CD4 T lymphocytes and recent thymic emigrants, 15 or more years after perinatal HIV infection The ANRS-EP38-IMMIP study Stéphane Blanche, Daniel.

Naive CD4 T lymphocytes and recent thymic emigrants, 15 or more years after perinatal HIV infection The ANRS-EP38-IMMIP study Stéphane Blanche, Daniel.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.

Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Increased phenotypic susceptibility (hypersusceptibility, HS) to NNRTIs is observed in ~30% of viral isolates with NRTI- resistance mutations 1 and has.

Increased phenotypic susceptibility (hypersusceptibility, HS) to NNRTIs is observed in ~30% of viral isolates with NRTI- resistance mutations 1 and has.
TO EVALUATE EARLY ANTIVIRAL RESPONSE AND SAFETY OF A DUAL BOOSTED PROTEASE INHIBITORS REGIMEN INCLUDING LOPINAVIR/r (LPV) PLUS AMPRENAVIR (AMP) OR FORTOVASE.

TO EVALUATE EARLY ANTIVIRAL RESPONSE AND SAFETY OF A DUAL BOOSTED PROTEASE INHIBITORS REGIMEN INCLUDING LOPINAVIR/r (LPV) PLUS AMPRENAVIR (AMP) OR FORTOVASE.
HIV Principles in Primary Care and Triage of the HIV patient David Aymond, MD, AAHIVM.

HIV Principles in Primary Care and Triage of the HIV patient David Aymond, MD, AAHIVM.
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA (Options in Management with Antiretrovirals) Trial Birgitt Dau, M.D. Postdoctoral.

Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA (Options in Management with Antiretrovirals) Trial Birgitt Dau, M.D. Postdoctoral.
Arnold School of Public Health Health Services, Policy, and Management 1 Drug Treatment Disparities Among African Americans Living with HIV/AIDS Carleen.

Arnold School of Public Health Health Services, Policy, and Management 1 Drug Treatment Disparities Among African Americans Living with HIV/AIDS Carleen.
Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.

Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.
Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial: Towards a Regimen-Based Resistance Interpretation J. M. Schapiro, J. Vingerhoets, S.

Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial: Towards a Regimen-Based Resistance Interpretation J. M. Schapiro, J. Vingerhoets, S.

Similar presentations

Ads by Google